Evidence map›Paper›PMID 38434193›Full record

ArticleSovremennye tekhnologii v meditsine2023

PhthisisBioMed Artificial Medical Intelligence: Software for Automated Analysis of Digital Chest X-ray/Fluorograms.

Y T Gogoberidze, V I Klassen, M Y Natenzon, I A Prosvirkin, A V Vladzimirsky, D E Sharova, V V Zinchenko

Open access · diamondAbstract read
In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Y T GogoberidzeSenior Development Engineer; PhthisisBioMed LLC, 135 Karla Marksa St., Chistopol, Republic of Tatarstan, 422980, Russia.
V I KlassenProfessor, General Director; RK Vector JSC, 135 Karla Marksa St., Chistopol, Republic of Tatarstan, 422980, Russia; Board Chairman; PhthisisBioMed LLC, 135 Karla Marksa St., Chistopol, Republic of Tatarstan, 422980, Russia.
M Y NatenzonSenior Researcher; Russian Academy of Sciences, 14 Leninsky Prospekt, Moscow, 119071, Russia; Chairman of the Board of Directors; Scientific and Production Association National Telemedicine Agency, Office 8, 9 Demyana Bednogo St., Moscow, 123423, Russia.
I A ProsvirkinIT Director; RK Vector JSC, 135 Karla Marksa St., Chistopol, Republic of Tatarstan, 422980, Russia.
A V VladzimirskyDeputy Director for Scientific Research; Scientific and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Department of Health, Bldg. 1, 24 Petrovka St., Moscow, 127051, Russia.
D E SharovaHead of Innovative Technologies Department; Scientific and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Department of Health, Bldg. 1, 24 Petrovka St., Moscow, 127051, Russia.
V V ZinchenkoHead of Clinical and Technical Trials Sector; Scientific and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Department of Health, Bldg. 1, 24 Petrovka St., Moscow, 127051, Russia.
Russian Scientific Center of Surgery · RUArtificial Intelligence in Medicine (Canada) · CAFederal Agency for Scientific Organizations · RURussian Academy of Sciences · RUSt. Mark's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The scope of diagnostic medical examinations increases from year to year causing a reasonable desire to develop and implement new technologies to diagnostics and medical data analysis. Artificial intelligence (AI) algorithms became one of the most promising solutions to this problem and proved themselves in the course of mass practical application. During the three-year Moscow experiment started in 2020, the possibility was achieved to develop methodologies of AI use and to successfully implement it into the regional level healthcare system. In this article, the authors share their experience in developing a medical AI service using the example of PhthisisBioMed AI service and the results of its application in real clinical activities environment. This AI service has shown its quality and reliability confirmed by technological monitoring. Clinical trials of PhthisisBioMed AI service were conducted on a specially prepared verified data set (n=1536) considering epidemiological indicators of the thoracic organs major diseases prevalence. The mean sensitivity of the service was 0.975 (95% CI: 0.966-0.984). PhthisisBioMed medical AI service is registered as a medical device (medical device registration certificate No.RZN 2022/17406 dated May 31, 2022) and is actively used in the Russian Federation as a diagnostic tool to reduce the burden on radiologists and to accelerate the process of medical report obtaining.

Indexed as

Artificial IntelligenceSoftwareIntelligenceReproducibility of ResultsX-Raysartificial medical intelligenceCDSSneural networksPhthisisBioMed AI servicethoracic organ diseasesURIS UMIAS

Identifiers

PMID38434193
PMCPMC10902898
OpenAlexW4386294688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.